Our previous data showed that high ARF mRNA level (relative expression >0.1) in the tumour corresponds to a good response to somatostatin analogues, while low ARF expression (<0.1) indicated resistance to somatostatin analogues [30]. The gene discussed is CDKN2A; the disease is neoplasm.